Healthcare stocks were leaning lower premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.2% and the iShares Biotechnology ETF (IBB) down 0.1%.
Definium Therapeutics (DFTX) shares were up more than 16% after the company said its phase 3 Voyage study of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.